Leadership

Ronald Christensen

Dr. Christensen has broad-based experience in academia, clinical research, and the biopharmaceutical industry.Following his fellowship training in Pediatric Endocrinology, he was Director of Endocrinology at Phoenix Children's Hospital.As a Director in both the Marketing and Medical Affairs Departments at Genentech, Inc., he provided expertise in development of observational studies to support clinical, safety, and product commercialization efforts. He was responsible for the design, implementation, and management of several patient registries in various therapeutic areas over a 10-year period.

As Senior Director of Medical Affairs at Genentech, Dr. Christensen was responsible for the management and direction of four groups: Medical Information, Drug Safety, Epidemiology, and Post-marketing Studies. These groups provided customer and product support for commercial products and were involved in the clinical development of new molecular entities.

In 1997, Stephen Webb and Dr. Christensen founded a contract research organization (CRO) focused on conducting peri- and post-approval studies that later became REGISTRAT^®, Inc. In June 2009, REGISTRAT merged with a MAPI Group company to form REGISTRAT-MAPI, a global Late Phase CRO. In addition to his role as a member of the Executive Committee, his administrative responsibilities as CEO include strategic oversight of North America business and operations and direct management of the Quality Assurance, Human Resources, Information Technology, and Business Development Departments.

During his 25 years in the biopharmaceutical industry, Dr. Christensen has become an industry leader in the development and application of Late Phase studies (peri- and post-approval studies) for post-marketing safety surveillance, clinical effectiveness, outcomes research, and risk management.He has been involved in the strategic design, implementation, and management of hundreds of Late Phase studies and Risk Management Programs.

William C. Maier

Dr. William C. Maier, is Chief Scientific Officer at REGISTRAT-MAPI the industry's largest clinical research organization (CRO) dedicated solely to real-world clinical research.

Dr. Maier has over 20 years of experience in drug development and commercialization at pharmaceutical companies in Europe and the United States. He was previously Senior Director of Epidemiology at GlaxoSmithKline and Elan Pharmaceuticals and led research groups conducting observational research using registries, databases, chart reviews and field research to support reimbursement, marketing and drug safety investigations of pharmaceuticals throughout the world. He has worked on over 50 observational studies in several disease areas including respiratory, neurology, psychiatry, autoimmune, cancer, endocrinology, cardiovascular, cerebrovascular, urology, opioid dependency and vaccines.

He routinely provides training seminars to pharmaceutical, biotechnology and medical products companies in Europe and the United States on the use and development of real-life data for use in health technology assessment, drug safety and risk management. In July 2007 he presented the Tysabri Risk Management Plan at an FDA advisory committee meeting.

Dr. Maier is editor of the quarterly PharmacoEpi and Risk Management Newsletter, (http://www.prmnewsletter.org/) which publishes articles on applications of methods, development of new tools and reflections on regulatory developments in product safety, pharmacoepidemiology and risk management.

He is also involved with the International Society of Pharmacoeconomics Research (ISPOR) project to develop a global database of real-life health care information (www.ispor.org/Intl_Databases/) and is a member of the EMEA's European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (www.encepp.eu). In addition, he is a frequent speaker at medical conferences and has academic appointments in the UK (Dundee) and the USA (North Carolina).

Nigel Page

MAPI Group is delighted to welcome the appointment of Nigel Page to the position of Chief Executive Officer for REGISTRAT-MAPI Europe.

Nigel has a successful track record with more than 27 years of experience in the Pharmaceutical and CRO industries and has demonstrated unique capabilities in building profitable organizations in complex, multidisciplinary, global environments. Nigel has worked for a variety of Pharmaceutical and CRO companies in the UK, the USA and Germany and has held key roles in Sales & Marketing, Regulatory, Clinical Operations, Systems & Quality Improvement, IT, M&A and General/Executive Management. He joins Registrat-Mapi from i3, where he held positions of President, i3 Research and Executive Vice President, Strategic Outsourcing & Corporate Development for the last 7 years.

"We are very fortunate Nigel has joined REGISTRAT-MAPI," said MAPI Group CEO Bernard Jambon. "Nigel is a world-recognized leader in the CRO industry and very clear about the business imperatives of a fast-moving company. He has enjoyed success in realizing aggressive growth and profitability objectives; establishing global operations and building strategic customer relationships across the world. The expertise which Nigel will bring to our Group including his leadership and management skills, industry knowledge and customer-centric philosophy will benefit not just REGISTRAT-MAPI but our client-base too."

"I am extremely pleased to join the MAPI Group " said Nigel. "I look forward to driving the ambitious growth strategy of REGISTRAT-MAPI in the expanding global market of Late Phase studies."

Stephen Webb

Mr. Webb is responsible for business and global operations, strategic consultation on study design and analyses, international affiliates, product commercialization, and client and business development activities for the company. Mr. Webb has been in the industry since 1988 marketing biopharmaceuticals, conducting clinical and basic research, and developing numerous peri- and post-approval studies including: Phase IIIb–IV studies; disease, product, and pregnancy registries; post-marketing commitment studies; and expanded safety surveillance and risk management programs.

Mr. Webb has held previous positions at Glaxo Pharmaceuticals, Research Triangle Park, NC as a Hospital/Field Sales Representative where he marketed oral and parenteral gastro-infectious disease and neurological pharmaceuticals, and ClinTrials Research where he managed Phase II–IV clinical studies for FDA submission and approvals with a concentration in Phase IV Post-Marketing Studies.

Mr. Webb is a graduate of the University of Kentucky where he majored in Business Administration and Biology, completed his premedical curriculum, and conducted basic research at the Center for Biomedical Engineering and Department of Anatomy and Neurobiology. Mr. Webb is a Fellow of the Howard Hughes Medical Institute, has authored published abstracts and scientific papers, and presents at numerous industry conferences.

Bernard Jambon

After earning his Masters degree in Law and Economics, and a year as a basketball player in the UK, Bernard Jambon founded MAPI in 1974. In 1981, he was joined by Jean-Louis Ménard.

Today, Mr. Jambon is associate chairman and CEO of MAPI Group, a world leader in Late Phase clinical trials, Pharmaco-Epidemiology and Market Access. MAPI Group focuses on drug evaluation studies with a specific emphasis on patient assessment and Late Phase evaluation.

Mr. Jambon was a teacher at the Lyon Business School (ESC) in 1976. He is founder and editor of the "PRO Newsletter" and "PRM Newsletter". He is a member of the editorial board of the "Journal of Epidemiology and Biostatistics." Mr. Jambon previously served on the Advisory Council of Europe for the Drug Information Association and on the Board of Directors of ISOQOL.